Immunogenic cell death in cancer and infectious disease

doi:10.1038/nri.2016.107

Review

. 2017 Feb;17(2):97-111.

doi: 10.1038/nri.2016.107. Epub 2016 Oct 17.

Immunogenic cell death in cancer and infectious disease

Lorenzo Galluzzi^{1

2

3

4

5

6}, Aitziber Buqué^{2

3

4

5

6}, Oliver Kepp^{2

3

4

5

7}, Laurence Zitvogel^{6

8

9

10}, Guido Kroemer^{2

3

4

5

7

11

12}

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, 10065 New York, New York, USA.
² Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, 75006 Paris, France.
³ INSERM, U1138, 75006 Paris, France.
⁴ Université Paris Descartes/Paris V, Sorbonne Paris Cité, 75006 Paris, France.
⁵ Université Pierre et Marie Curie/Paris VI, 75006 Paris, France.
⁶ Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif, France.
⁷ Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif, France.
⁸ INSERM, U1015, 94805 Villejuif, France.
⁹ Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, 94805 Villejuif, France.
¹⁰ Université Paris Sud/Paris XI, 94270 Le Kremlin-Bicêtre, France.
¹¹ Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden.
¹² Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP, 75015 Paris, France.

PMID: 27748397
DOI: 10.1038/nri.2016.107

Review

Immunogenic cell death in cancer and infectious disease

Lorenzo Galluzzi et al. Nat Rev Immunol. 2017 Feb.

. 2017 Feb;17(2):97-111.

doi: 10.1038/nri.2016.107. Epub 2016 Oct 17.

Authors

Lorenzo Galluzzi^{1

2

3

4

5

6}, Aitziber Buqué^{2

3

4

5

6}, Oliver Kepp^{2

3

4

5

7}, Laurence Zitvogel^{6

8

9

10}, Guido Kroemer^{2

3

4

5

7

11

12}

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, 10065 New York, New York, USA.
² Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, 75006 Paris, France.
³ INSERM, U1138, 75006 Paris, France.
⁴ Université Paris Descartes/Paris V, Sorbonne Paris Cité, 75006 Paris, France.
⁵ Université Pierre et Marie Curie/Paris VI, 75006 Paris, France.
⁶ Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif, France.
⁷ Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif, France.
⁸ INSERM, U1015, 94805 Villejuif, France.
⁹ Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, 94805 Villejuif, France.
¹⁰ Université Paris Sud/Paris XI, 94270 Le Kremlin-Bicêtre, France.
¹¹ Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden.
¹² Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP, 75015 Paris, France.

PMID: 27748397
DOI: 10.1038/nri.2016.107

Abstract

Immunogenicity depends on two key factors: antigenicity and adjuvanticity. The presence of exogenous or mutated antigens explains why infected cells and malignant cells can initiate an adaptive immune response provided that the cells also emit adjuvant signals as a consequence of cellular stress and death. Several infectious pathogens have devised strategies to control cell death and limit the emission of danger signals from dying cells, thereby avoiding immune recognition. Similarly, cancer cells often escape immunosurveillance owing to defects in the molecular machinery that underlies the release of endogenous adjuvants. Here, we review current knowledge on the mechanisms that underlie the activation of immune responses against dying cells and their pathophysiological relevance.

PubMed Disclaimer

Comment in

The complement system is also important in immunogenic cell death.
Jin J, He S. Jin J, et al. Nat Rev Immunol. 2017 Feb;17(2):143. doi: 10.1038/nri.2016.142. Epub 2016 Dec 28. Nat Rev Immunol. 2017. PMID: 28028311 No abstract available.
Reply: The complement system is also important in immunogenic cell death.
Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Galluzzi L, et al. Nat Rev Immunol. 2017 Feb;17(2):143. doi: 10.1038/nri.2016.143. Epub 2016 Dec 28. Nat Rev Immunol. 2017. PMID: 28028312 No abstract available.
Reply: Immunosuppressive cell death in cancer.
Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Galluzzi L, et al. Nat Rev Immunol. 2017 Jun;17(6):402. doi: 10.1038/nri.2017.48. Epub 2017 May 8. Nat Rev Immunol. 2017. PMID: 28480896 No abstract available.
Immunosuppressive cell death in cancer.
Hou J, Greten TF, Xia Q. Hou J, et al. Nat Rev Immunol. 2017 Jun;17(6):401. doi: 10.1038/nri.2017.46. Epub 2017 May 8. Nat Rev Immunol. 2017. PMID: 28480899 Free PMC article. No abstract available.

Cited by

Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S, Nelson A, Walker B, Oliphant T, Lobert L, Mahoney D, Johnston B. Gebremeskel S, et al. J Immunother Cancer. 2021 Mar;9(3):e002096. doi: 10.1136/jitc-2020-002096. J Immunother Cancer. 2021. PMID: 33722907 Free PMC article.
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.
Maines LW, Keller SN, Smith CD. Maines LW, et al. Int J Mol Sci. 2023 Nov 29;24(23):16901. doi: 10.3390/ijms242316901. Int J Mol Sci. 2023. PMID: 38069222 Free PMC article.
Bacteria-Based Cancer Immunotherapy.
Huang X, Pan J, Xu F, Shao B, Wang Y, Guo X, Zhou S. Huang X, et al. Adv Sci (Weinh). 2021 Feb 10;8(7):2003572. doi: 10.1002/advs.202003572. eCollection 2021 Apr. Adv Sci (Weinh). 2021. PMID: 33854892 Free PMC article. Review.
Contribution of annexin A1 to anticancer immunosurveillance.
Baracco EE, Stoll G, Van Endert P, Zitvogel L, Vacchelli E, Kroemer G. Baracco EE, et al. Oncoimmunology. 2019 Aug 14;8(11):e1647760. doi: 10.1080/2162402X.2019.1647760. eCollection 2019. Oncoimmunology. 2019. PMID: 32923172 Free PMC article.
Calreticulin as a prognostic biomarker and correlated with immune infiltrate in kidney renal clear cell carcinoma.
Sun M, Qi S, Wu M, Xia W, Xiong H. Sun M, et al. Front Genet. 2022 Oct 21;13:909556. doi: 10.3389/fgene.2022.909556. eCollection 2022. Front Genet. 2022. PMID: 36338983 Free PMC article.

See all "Cited by" articles

References

1. PLoS One. 2012;7(3):e31732 - PubMed
1. Nat Rev Immunol. 2015 Jul;15(7):405-14 - PubMed
1. Nat Rev Cancer. 2016 Apr;16(4):219-33 - PubMed
1. Annu Rev Immunol. 2010;28:367-88 - PubMed
1. Vaccine. 2015 Dec 16;33(51):7415-22 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] PLoS One. 2012;7(3):e31732 - PubMed

[2] PLoS One. 2012;7(3):e31732 - PubMed

[3] Nat Rev Immunol. 2015 Jul;15(7):405-14 - PubMed

[4] Nat Rev Immunol. 2015 Jul;15(7):405-14 - PubMed

[5] Nat Rev Cancer. 2016 Apr;16(4):219-33 - PubMed

[6] Nat Rev Cancer. 2016 Apr;16(4):219-33 - PubMed

[7] Annu Rev Immunol. 2010;28:367-88 - PubMed

[8] Annu Rev Immunol. 2010;28:367-88 - PubMed

[9] Vaccine. 2015 Dec 16;33(51):7415-22 - PubMed

[10] Vaccine. 2015 Dec 16;33(51):7415-22 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunogenic cell death in cancer and infectious disease

Affiliations

Immunogenic cell death in cancer and infectious disease

Authors

Affiliations

Abstract

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical